Background

FDA Issues Urgent Notice Regarding Oxbryta, a Pfizer Pharmaceutical Drug

Hable con un abogado
oxbryta

Oxbryta / Voxelotor Withdrawn From Market Due To Serious Health Risks

Sickle Cell Disease Patients May Be Entitled To Compensation

In September 2024, the FDA issued a formal alert to patients, caregivers, and healthcare professionals, recommending the discontinuation of Oxbryta prescriptions. Oxbryta (voxelotor) is a medication manufactured by Pfizer that had been approved to manage sickle cell disease (SCD). However, studies revealed an increased risk of vaso-occlusive crises and mortality in patients who were taking this drug.

CohenMalad, LLP is actively investigating legal claims related to Oxbryta injuries. If you or a loved one suffered adverse effects after using Oxbryta, contact our experienced pharmaceutical drug attorney team to learn your rights and options.

Understanding Vaso-Occlusive Crises in Sickle Cell Disease

Sickle cell disease is a genetic disorder that alters red blood cell shape, hindering oxygen flow throughout the body. This condition leads to chronic pain, delayed growth, blood clots, and life-threatening complications. These often impact the lungs (acute chest syndrome), spleen, liver, kidneys, and brain. Patients with SCD face higher risks of infections, joint issues, gallstones, and even silent brain injury, which occurs without noticeable stroke symptoms.

A vaso-occlusive crisis is a painful, potentially life-threatening condition where misshaped red blood cells block blood flow, preventing oxygen from reaching tissues. Symptoms often include moderate to severe pain, frequently occurring in the extremities, chest, and back. Children may experience swelling in their hands and feet.

Patients on Oxbryta were at an increased risk for these crises and were more likely to experience fatal outcomes, making the risks of the drug unacceptable for continued use.

Legal Support for Patients Harmed by Oxbryta

As a patient-focused law firm, CohenMalad, LLP is dedicated to seeking justice for individuals impacted by Oxbryta’s adverse effects. Our experienced team of pharmaceutical attorneys is currently reviewing claims from those who experienced vaso-occlusive crises or the loss of a loved one after using Oxbryta.

If you or someone you care about suffered from complications due to Oxbryta, you may be eligible for compensation. CohenMalad, LLP offers free consultations to discuss your legal options and potential claims. Our experienced pharmaceutical drug litigation attorneys are here to answer your questions and assist you in pursuing your rights. With a deep commitment to helping clients in drug injury cases, we will guide you through each step of the legal process to help secure the compensation you deserve.

CTA back

Take Action — Contact CohenMalad, LLP Today

Meet Our Pharmaceutical Litigation Team

Our legal team has spent years fighting against big pharmaceutical companies that put dangerous drugs on the market. We have the resources, experience, and aggressive litigation skills needed to win these cases.

When you hire CohenMalad, LLP, you’re not just getting an attorney — you’re getting a team of fighters dedicated to securing justice for victims like you.

acerca de nosotros
Team photo

Contact us today

so that a knowledgeable product liability lawyer from CohenMalad, LLP can provide you with a free case evaluation and discuss your legal options.

El nombre no es válido
El apellido no es válido
El teléfono no es válido
El correo electrónico no es válido
Este campo es obligatorio
Este campo es obligatorio
Este campo es obligatorio
      Este campo es obligatorio

      Al proporcionar un número de teléfono y enviar el formulario, usted acepta que nos comuniquemos con usted por mensaje de texto SMS. Es posible que se apliquen tarifas por mensajes y datos. Responda STOP para dejar de recibir más mensajes.

      ¡Gracias!
      Su mensaje ha sido enviado
      ¡Uy! Algo salió mal al enviar el formulario.